Nurami has been chosen to receive a €2.5M by the European Commission under the prestigious European Innovation Council (EIC) Accelerator program. The EIC has also expressed a material commitment to support the continued development of ArtiFix, Nurami’s groundbreaking dural sealant patch via an additional equity investment. The grant will fund preliminary clinical trials of ArtiFix and the beginning of the planned pivotal trials, while the additional equity investment, together with Nurami’s series B investment will support efforts through regulatory approval in the EU and the US, as well as preliminary marketing efforts.
